Veracyte | VCYT - Ebitda


Veracyte reported $41.24M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Agilent USD 577M 77M Jun/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -212.62M 64.94M Sep/2026
Bruker USD 143.2M 33.2M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Illumina USD 330M 80M Jun/2026
Intrexon USD -24.7M 2.92M Jun/2024
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Laboratory Of America USD 674.3M 93.4M Sep/2026
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Roche Holding CHF 13.43B 744M Jun/2026
Siemens EUR 4.57B 366M Sep/2026
Sonic Healthcare AUD 839.07M 51.09M Dec/2024
Thermo Fisher Scientific USD 3.79B 244M Sep/2026
Veracyte USD 41.24M 2.72M Sep/2026
Waters USD 554M 158M Sep/2026